

1. American Diabetes Association. Clinical Practice Recommendations 2000. *Diabetes Care*, 23 (Suppl. 1): S1-116, 2000.
2. Implications of the United Kingdom Prospective Diabetes Study. *Diabetes Care*, 21: 2180-2184, 1998.
3. Hoet JJ, Tripathy BB, Rao RH, Yajnik CS. Malnutrition and diabetes in the tropics. *Diabetes Care*, 19: 1014-1017, 1996.
4. Atkinson MA, Maclaren NK. The pathogenesis of insulin dependent diabetes. *N Engl J Med*, 331: 1428-1436, 1994.
5. Baekkeskov S, Neilsen JH, Marnier B, et al. Autoantibodies in newly diagnosed diabetic children with immunoprecipitate human pancreatic islet cell proteins. *Nature*, 298: 167-169, 1982.
6. Kaufman D, Erlander M, Clare-Salzler M, et al. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. *J Clin Invest*, 89: 283-292, 1992.
7. Schmidli RS, Colman PG, Harrison LC. Do glutamic acid decarboxylase antibodies improve the prediction of IDDM in first-degree relatives at risk for IDDM? *J Autoimmunity*, 7: 873-879, 1994.
8. Lu J, Li Q, Xie H, et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. *Proc Natl Acad Sci USA*, 93: 2307-2311, 1996.
9. Zimmet PZ, Tuomi T, Mackay R, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. *Diabet Med*, 11: 299-303, 1994.
10. Banerji M, Lebovitz H. Insulin sensitive and insulin resistant variants in IDDM. *Diabetes*, 38: 784-792, 1989.
11. Reaven GM, Bernstein R, Davis B, Olefsky JM. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? *Am J Med*, 60: 80-88, 1976.
12. Olefsky JM, Kolterman OG, Scarlett, JA. Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. *Am J Physiol*, 243: E15-E30, 1982.
13. Harris MI. Impaired glucose tolerance in the U.S. population. *Diabetes Care*, 12: 464-474, 1989.
14. Moss SE, Klein R, Klein BEK, Meuer MS. The association of glycemia and cause-specific mortality in a diabetic population. *Arch Int Med*, 154: 2473-2479, 1984.
15. Uusitupaa MII, Niskanen LK, Siitonen O, et al. Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. *Diabetologia*, 18: 1534-1543, 1993.
16. Butkiewicz EK, Leibson C, O'Brien PC, et al. Insulin therapy for diabetic ketoacidosis. *Diabetes Care*, 18: 1187-1190, 1995.
17. Banerji MA, Chaiken RL, Huey H, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. *Diabetes*, 43: 741-745, 1994.
18. Harris MI, Couric CC, Reiber G, Boyko E, Stern M, Bennett P (Eds.): *Diabetes in America*. 2nd edition, Washington, DC, U.S. Govt. Printing Office, (NIH publ. no. 95-1468) 1995.
19. Zimmet PZ. Kelly West Lecture 1991: challenges in diabetes epidemiology: from west to the rest. *Diabetes Care*, 15: 232-252, 1992.
20. Kolterman OG, Gray RS, Griffin J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. *J Clin Invest*, 68: 957-969, 1981.
21. Bogardus C, Lillioja S, Mott DM, et al. Relationship between degree of obesity and in vivo insulin action in man. *Am J Physiol*, 248: E286-E291, 1985.
22. Fujimoto WY, Leonetti DL, Kinyoun JL, et al. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance or normal glucose tolerance. *Diabetes*, 36: 730-739, 1987.
23. Newman B, Selby JV, Slemenda C, et al. Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. *Diabetologia*, 30: 763-738, 1987.
24. Herman WH, Fajans SS, Oritz FJ, et al. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. *Diabetes*, 43: 40-46, 1994.
25. Clement K, Pueyo ME, Vaxillaire M, et al. Assessment of

- insulin sensitivity in glucokinase-deficient subjects. *Diabetologia*, 39: 82–90, 1996.
26. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1 gene in maturity-onset diabetes of the young (MODY 3). *Nature*, 384: 455–458, 1996.
  27. Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. *Nature*, 356: 162–164, 1992.
  28. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte factor-4 gene in maturity-onset diabetes of the young (MODY 1). *Nature*, 384: 458–460, 1996.
  29. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. *N Engl J Med*, 294: 739–745, 1976.
  30. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin-receptor gene. *Diabetes*, 41: 1473–1490, 1992.
  31. Schwartz SS, Zeidler A, Moossa AR, et al. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. *Digestive Dis*, 23: 1107–1114, 1978.
  32. Larsen S, Hilsted J, Tronier B, Worning H. Metabolic control and B cell function in patients with insulin-dependent diabetes mellitus secondary to chronic pancreatitis. *Metabolism*, 36: 964–967, 1987.
  33. Berelowitz M, Eugene HG. Non-insulin dependent diabetes mellitus secondary to other endocrine disorders. In: *Diabetes Mellitus*. LeRoith D, Taylor SI, Olefsky JM, Eds. New York, Lippincott-Raven, 1996, p. 496–502.
  34. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. *N Engl J Med*, 273: 1135–1143, 1965.
  35. Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders of glucose tolerance. *Ann Int Med*, 118: 529–540, 1993.
  36. Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. *Diabetes Care*, 18: 47–55, 1995.
  37. Gallanosa AG, Spyker DA, Curnow RT. Diabetes mellitus associated with autonomic and peripheral neuropathy after Vacor poisoning: a review. *Clin Toxicol*, 18: 441–449, 1981.
  38. King ML, Bidwell D, Shaikh A, et al. Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus. *Lancet*, i: 1397–1399, 1983.
  39. Pak CY, Eun H, McArthur RG, Yoon J. Association of cytomegalovirus infection with autoimmune type 1 diabetes. *Lancet*, ii: 1–4, 1988.
  40. Solimena M, Folli, Aparisi R, et al. Autoantibodies to GABA-nergic neurons and pancreatic beta cells in stiff-man syndrome. *N Engl J Med*, 41: 347–353, 1992.
  41. Rimoin DL. Genetic syndromes associated with glucose intolerance. In: *The Genetics of Diabetes Mellitus*. Berlin, Springer-Verlag, 1976.
  42. Metzger BE, Organizing Committee. Summary and recommendations of the Third International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes*, 40: 197–201, 1991.
  43. Metzger BE, Cho NH, Roston SM, Radvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. *Diabetes Care*, 16: 1598–1605, 1993.
  44. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care*, 21 (Suppl. 2): B161–B167, 1998.
  45. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes*, 28: 1039–1057, 1979.
  46. World Health Organization. *Diabetes Mellitus: Report of a WHO Study Group*. Geneva, World Health Org., (Tech. Rep. Ser., no. 727), 1985.
  47. Rose DB. *Clinical Physiology of Acid-Base and Electrolyte Disorders*. 4th edition, McGraw-Hill, New York, pp. 737–748, 1994.
  48. Zierler KL, Rabinowitz D. Effects of very small concentrations of insulin on forearm metabolism. Persistence of its action on potassium and free fatty acids without its effect on glucose. *J Clin Invest*, 43: 950–956, 1964.
  49. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. *N Engl J Med*, 329: 977–986, 1993.
  50. UK Prospective Diabetes Study Group. Tight blood pressure control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*, 352: 837–853, 1998.
  51. Koenig RJ, Cerami A. Synthesis of hemoglobin A1c in normal and diabetic mice: potential model of basement membrane thickening. *Proc Natl Acad Sci USA*, 72: 3687–3691, 1975.
  52. Brownlee M. Glycation and Diabetic Complications. *Diabetes*, 43: 836–841, 1994.
  53. Cochrane SM, Robinson GB. In vitro glycation of glomerular basement membrane alters its permeability: a possible mechanism in diabetic complications. *FEBS Lett*, 375: 41–44, 1995.
  54. Pricci F, Leto G, Amadio L, et al. Role of galectin-3 as a receptor for advanced glycosylation end products. *Kidney*

- Int, 58: (S77) S31–S39, 2000.
55. Nishikawa T, Edelstein D, Brownlee M. The missing link: A single unifying mechanism for diabetic complications. *Kidney Int*, 58: (S77) S26–S30, 2000.
  56. Ruderman N, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. *FASEB J*, 6: 2905–2914, 1992.
  57. Lee HB, Cha MK, Song Kim JH, et al. Pathogenetic role of advanced glycosilation end products in diabetic nephropathy. *Kidney Int*, 52: (8S60) S60–S65, 1997.
  58. Al-Abed Y, Mitsuhashi L, Lawson JA, et al. Inhibition of advanced glycation end product formation by acetaldehyde: role in the cardioprotective effect of ethanol. *Proc Natl Acad Sci USA*, 96: 2385–2390, 1999.
  59. Haneda M, Kikkawa R, Arimura T, et al. Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. *Metabolism*, 39: 40–45, 1990.
  60. Cohen MP, Klepser H. Glomerular Na<sup>+</sup>/K<sup>+</sup> ATPase activity in acute and chronic diabetes and with aldose reductase inhibition. *Diabetes*, 37: 558–562, 1988.
  61. Niwa T. 3-deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. *J Chromat Biomed Sci Appl*, 731: 23–36, 1999.
  62. Ha H, Lee HB. Reactive oxygene species as glucose signaling molecules in mesangial cells cultured under high glucose. *Kidney Int*, 58 (S77): S19–S25, 2000.
  63. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. *Kidney Int*, 58 (S77): S3–S12, 2000.
  64. Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: Proposal for mechanism in the development of diabetic vascular complications. *Proc Acad Natl Sci USA*, 86: 5141–5145, 1989.
  65. Hempel A, Maasch C, Heintze U, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C $\alpha$ . *Cir Res*, 81: 363–371, 1997.
  66. Ishii H, Jrousek MR, Koya D, et al. Amelioration of vascular dysfunction in diabetic rats by oral PKC  $\alpha$  inhibitor. *Science*, 272: 728–731, 1996.
  67. Nishikawa T, Edelstein D, Brownlee M. The missing link unifying mechanism for diabetic complications. *Kidney Int*, 58 (S77): S26–S30, 2000.
  68. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF  $\alpha$  gene expression and bioactivity in proximal tubule. *Kidney Int*, 41: 107–114, 1992.
  69. Ziyadeh FN. Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. *Miner Electrolyte Metab*, 21: 292–302, 1995.
  70. Cha DR, Kim NH, Yoon JW, et al. Role of vascular endothelial growth factor in diabetic nephropathy. *Kidney Int*, 58 (S58): S104–S112, 2000.
  71. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. *Lancet*, 339: 1128–1130, 1992.
  72. Mitchell BD, Hawthorne VN, Vinik A. Cigarette smoking and neuropathy in diabetic patients. *Diabetes Care*, 13: 434–437, 1990.
  73. The World Health Organization Multinational Study Group. Which feature of smoking determine mortality risk in former cigarette smokers with diabetes? *Diabetes Care*, 20: 1266–1272, 1997.
  74. Treatment recommendations of the National Cholesterol Educational Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. *Pediatrics*, 89: 525–584, 1992.
  75. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *JAMA*, 269: 3015–3023, 1993.
  76. Uusitupa MII, Niskanen LK, Siitonen O, et al. Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. *Diabetologia*, 36: 1174–1184, 1993.
  77. De Fronzo RA, Ferranini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care*, 14: 173–194, 1991.
  78. Kaplan MN. Obesity, insulin and hypertension. *Cardiovascular Risk Factors*, 4: 133–141, 1994.
  79. Williams B. Insulin Resistance: the shape of things to come. *Lancet*, 344: 521–524, 1994.
  80. National Diabetes Data Group. *Diabetes in America*. Bethesda, MD: National Institutes of Arthritis, Diabetes, and Digestive and Kidney Diseases. NIH publication n. 85-1468, 1985.
  81. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. *Diabetologia*, 14: 363–377, 1978.
  82. Klein R, Klein BEK, Moss SE, et al. Glycosilated hemoglobin predicts the incidence and progression of diabetic retinopathy. *JAMA*, 260: 2864–2871, 1988.
  83. The expert committee on the diagnosis and classification of diabetes mellitus. Report of expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*, 20: 1183–1197, 1997.
  84. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. *Diabetes*, 32: 64–78, 1983.
  85. Mogensen CE. Prediction of clinical diabetic nephro-

- pathy in IDDM patients. *Diabetes*, 39: 761–767, 1990.
86. Krolewski AS, Laffel LMB, Krolewski M, et al. Glycosylated Hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. *N Engl J Med*, 332: 1251–1255, 1995.
  87. Bojestig M, Arnqvist HJ, Hermansson G, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. *N Engl J Med*, 330: 15–18, 1994.
  88. Klein R, Klein BE, Moss SE, et al. Wisconsin Epidemiologic Study of diabetic Retinopathy: Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. *Arch Ophthalmol*, 102: 527, 1984.
  89. Klein R, Klein BE. Vision disorders in diabetes. In: *Diabetes in America*, DHHS Publ. n° 85-1468. U.S. Government Printing Office, 1985, pp 1–2.
  90. Sands ML, Shetterly SM, Franklin GM, et al. Incidence of distal symmetric (sensory) neuropathy in NIDDM. *Diabetes Care*, 20: 322, 1997.
  91. Forrest KY, Maser RE, Pambianco G. Hypertension as a risk factor for diabetic neuropathy. A prospective study. *Diabetes*, 46: 665–670, 1997.
  92. Dyck PJ, Karnes JL, O'Brien PC. Rochester Diabetic Neuropathy Study: Reassessment of tests and criteria of diagnosis and staged severity. *Neurology*, 42: 1164, 1993.
  93. Kuusisto J, Mykkanen L, Parola K et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. *Diabetes*, 43: 960, 1994.
  94. Abaira, C, Colwell, J, Nuttal, F et al. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes (VACSDM) Cardiovascular events and correlates in the VA feasibility trial (VACSDM). *Arch Intern Med*, 157: 181, 1997.
  95. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. OHT Study Group. *Lancet*, 351: 1755–1762, 1998.
  96. Mogensen, CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy (editorial). *BMJ*, 317: 693, 1998.
  97. Diabetes Control and Complication Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complication trial. *Diabetes*, 44: 968–983, 1995.
  98. Fluckiger R, Harmon W, Maier W et al. Hemoglobin carbamylation in uremia. *N Engl J Med*, 304: 823, 1981.
  99. The DCCT Research Group. Diabetes Control and Complication Trial (DCCT): result of feasibility study. *Diabetes Care*, 10: 1, 1987.
  100. Koivisto VA. Diabetes in the elderly: What role for exercise? *Geriatrics*, 181: 36–74.
  101. Henriksson J. Effects of physical training on the metabolism of skeletal muscle. *Diabetes Care*, 15: 1701, 1992.
  102. Rodnick KJ, Holloszy JO, Mondon CE, James DE. Effects of exercise training on insulin-regulatable glucose-transporter protein levels in rat skeletal muscle. *Diabetes*, 39: 1425, 1990.
  103. Deylin JT. Effects of exercise on insulin sensitivity in humans. *Diabetes Care*, 15: 1690, 1992.
  104. Berger M, Borchtold P, Cuppers HJ, et al. Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. *Diabetologia*, 13: 355, 1977.
  105. Koivisto PA, Felig P. Effects of leg exercise on insulin absorption in diabetic patients. *N Engl J Med*, 208: 79, 1978.
  106. Schneider S H, Amorosa LK, Khachadurian AK, Kuderian NB. Studies on mechanism on improved glucose control during regular exercise in type 2 (non insulin-dependent) diabetes. *Diabetologia*, 26: 355, 1984.
  107. Bogardus C, Ravussin R, Robins DC, et al. Effects of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. *Diabetes*, 33: 311, 1984.
  108. Yamanouchi K, Shinozaki T, Chikada K, et al. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. *Diabetes Care*, 18: 775–778, 1995.
  109. Schneider SH, Khachadurian AK, Amorosa LF et al. Ten-year experience with exercise-based out patient life-style modification program in the treatment of diabetes mellitus. *Diabetes Care*, 15: 1800, 1992.
  110. Zinmann B, Zuniga Guajardo S, Kelly D. Comparison of the acute and long-term effects of exercise on glucose control in type 1 diabetes. *Diabetes Care*, 7: 515, 1984.
  111. Soo K, Furler SM, Samaras B et al. Glycemic responses to exercise in IDDM after simple and complex carbohydrate supplementation. *Diabetes Care*, 19: 575, 1996.
  112. Armstrong JJ. A brief overview of diabetes mellitus and exercise. *Diabetes Educ*, 17: 175, 1991.
  113. Long BJ, Calfas KJ, Wooten W, et al. A multisite field test of the acceptability of physical activity counseling in primary care: Project PACE. *Am J Prev Med*, 12: 73, 1996.
  114. Calfas KJ, Long BJ, Sallis JF, et al. A controlled trial of physician counseling to promote the adoption of physical activity. *Prev Med*, 25: 225, 1996.
  115. McNiven, Temple MV, Bar-Or O, Riddell MC. The reliability and repeatability of the blood glucose response to prolonged exercise in adolescent boys with IDDM. *Diabetes Care*, 92: 59, 1995.
  116. Koivisto VA, Felig P. Alterations in insulin absorption and in the blood glucose control associated with varying insulin injection sites in diabetic patients. *Ann Intern Med*,

- 18: 326, 1980.
117. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMI*, 317: 703–713, 1998.
  118. Foster DW. Diabetes Mellitus. In: Harrison's Principles of Internal Medicine, 12th edition, JD Wilson, E Braunwald, KJ Iesselbacher, RG Petersdorf, JB Martin, AS Fauci, RK Rooy (eds), McGrawHill, Inc, New York, 1991, pp 1739–1759.
  119. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. *Diabetes Care*, 18: 843–51, 1995.
  120. Woodworth JR, Howey DC, Bowsher RR, et al. Comparative pharmacokinetics and glucodynamics in of two humans insulin mixtures. *Diabetes Care*, 17: 336–371, 1994.
  121. Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. *Diabetes Med*, 2: 45–53, 1985.
  122. American Diabetes Association. Standards of Medical Care for Patients With Diabetes mellitus. *Diabetes Care*, 23 (Suppl 1) 2000.
  123. Mecklenburg RS, Benson EA, Benson JW, et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. *JAMA*, 252: 3265–3269, 1984.
  124. Mecklenburg RS, Guinn TS, Sannar CA, Blumenstein BA. Multifunction continuous subcutaneous insulin infusion system: a one year prospective study of 127 patients. *Diabetes Care*, 9: 351–355, 1986.
  125. White JR. The Pharmacological Reduction of Blood Glucose in Patients with Type Diabete mellitus. *Clinical Diabetes* 16 Number 2, 1998.
  126. Gerich JE. Oral hypoglycemic agents. *N Engl J Med*, 321: 1232–1245, 1989.
  127. Vinambres C, Villanueva-Pancarillo ML, Valverde I, Malaisse WJ. Repanglidine preserves nutrient-stimulated biosynthesis activity in rat pancreatic islets. *Pharmacol Res*, 34: 83–85, 1996.
  128. Bailey CJ. Metformin, an update. *Gen Pharmacol*, 24: 1299–1309, 1993.
  129. De Fronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean NIDDM subjects, *J Clin Endocrinol Metab*, 73: 1294–1301, 1993.
  130. De Fronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with NIDDM. *N Engl J Med*, 333: 541–549, 1995.
  131. Iwamoto y, Kosaka K, Kuzuya Akanuma Y, et al. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. *Diabetes Care*, 19: 151–156, 1996.
  132. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone (letter). *N Engl J Med*, 338: 916, 1998.
  133. Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin dependent diabetes mellitus. *Drug Safety*, 11: 432–444, 1994.
  134. Connif RF, Shapiro JA, Seaton TB. Long term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. *Arch Intern Med*, 154: 2442–2448, 1994.
  135. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. *Ann Intern Med*, 121: 928–935, 1994.
  136. Pugh JA, Wagner ML, Sawyer J, et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A meta-analysis. *Diabetes Care*, 15: 953–959, 1992.
  137. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes: a meta-analysis of randomized, placebo-controlled studies. *Arch Intern Med*, 156: 259–264, 1996.
  138. Sabbatini M, Sansone G, Uccello F, et al. Early glycosylation products induce glomerular hyperfiltration in normal rats. *Kidney Int*, 42: 875–881, 1992.
  139. Christensen CK, Christensen JS, Schmitz A, et al. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients. A 2 year controlled study. *J Diabetic Complications*, 1: 91–95, 1987.
  140. Mogensen CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy. *BMI*, 304: 327–328, 1992.
  141. Fioretto P, Steffes MW, Surtherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. *N Engl J Med*, 339: 69–75, 1998.
  142. Bending JJ, Pickup JC, Viberti GC, Keen H. Glycaemic control in diabetic nephropathy. *BMI*, 288: 1187–1191, 1984.
  143. Viberti GC, Bilous RW, Mackintosh D, et al. Long term correction of hyperglycaemia and progression of renal failure in insulin-dependent diabetes. *BMI*, 286: 598–602, 1983.
  144. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. *Nephron*, 61: 377, 1992.
  145. Adrogue HJ. Glucose homeostasis and the kidney. *Kidney Int*, 42: 1266, 1992.
  146. Rabkin R, Rubenstein AH, Colwell JA. Glomerular filtration and proximal tubular absorption of insulin 131I. *Am J Physiol*, 223: 1093, 1972.
  147. Borissova AM, Djambazzova A, Todorov K, et al. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on Hemodialysis.

- Nephrol Dial Transplant, 8: 93, 1993.
148. Castellino P, Solino A, Luzi L, et al. Glucose and amino acid metabolism in chronic renal failure: Effects of insulin and amino acid. *Am J Physiol*, 262: F 168, 1992.
  149. Goecke IA, Bonilla S, Marusic, et al. Enhanced insulin sensitivity in extrarenal potassium handling in uremic rat. *Kidney Int*, 39: 39, 1991.
  150. Rabkin R, Simon NM, Steiner S, et al. Effects of renal disease on renal uptake and excretion of insulin in man. *N Engl J Med*, 282: 182, 1970.
  151. Herry RR, Schaeffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in non-insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab*, 61: 917, 1985.
  152. Wing RR, Blair E, Bodoni P, et al. Caloric restriction per se is a significant factor in improvement in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. *Diabetes Care*, 17: 30, 1994.
  153. United Kingdom Prospective Diabetes Study Group. (UKPDS):VII. Response of fasting blood glucose to dietary therapy in newly presenting type II diabetic patients. *Metabolism*, 39: 905, 1990.
  154. Rivellese A, Riccardi G, Pacioni D, et al. Effect of dietary fiber on glucose control and serum lipoprotein in diabetic patients. *Lancet*, ii: 447, 1980.
  155. Jenkins DJA, Wolever TMS, Jenkins AL, et al. The glycaemic index of foods tested in diabetic patients: a new basis for carbohydrate exchange favouring the use of legumes. *Diabetologia*, 24: 257, 1983.
  156. Jenkins DJA, Wolever TMS, Jenkins AL, et al. The glycaemic response to carbohydrate foods. *Lancet*, ii: 388, 1984.
  157. Nath KA, Kren SA, Hostetter TH. Dietary protein restriction in established renal injury in the rat. *J Clin Invest*, 78: 1199-1205, 1986.
  158. Mauer SM, Steffes MW, Azar S, Brown DM. Effect of dietary protein content in streptozotocin-diabetic rats. *Kidney Int*, 35: 48-59, 1989.
  159. Hostetter TH, Meyer TW, Rennke HG, Brenner BM. Chronic effects of dietary of dietary protein in the rat with intact and reduced renal mass. *Kidney Int*, 30: 509-517, 1986.
  160. El Nahas AM, Paraskevaku H, Zoob S, et al. Effect of dietary protein restriction on the development of renal failure after subtotal nephrectomy in rats. *Clin Sci*, 65: 399-406, 1983.
  161. Fukui M, Nakamura T, Ebihara I, et al. Low-protein diet attenuates increased gene expression of platelet-derived growth factor and transforming growth factor beta in experimental glomerular sclerosis. *J Lab Clin Med*, 121: 224, 1993.
  162. Nakamura T, Fukui M, Ebihara I, et al. Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis. *Kidney Int*, 45: 1593, 1994.
  163. Hirschberg R, Kopple JD. Response of insulin-like growth factor I and renal hemodynamics to a high and low-protein diet in the rats. *J Am Soc Nephrol*, 1: 1034, 1991.
  164. Jaffa AA, Vio CP, Silva RH, et al. Evidence for renal kinins as mediator of amino acid-induced hyperperfusion and hyperfiltration in the rat. *J Clin Invest*, 89: 1460, 1992.
  165. Zeller K, Whittaker E, Sullivan L, et al. Effect of restriction dietary protein on renal failure in patient with insulin-dependent diabetes mellitus. *N Engl J Med*, 324: 78-84, 1993.
  166. Klahr S, Levey AS, Bech GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. *N Engl J Med*, 303: 877, 1994.
  167. Zeller K, Whittaker E, Sullivan L, et al. Effects of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. *N Engl J Med*, 324: 78, 1991.
  168. Rosman JB, Langer K, Brandt M, et al. Protein restricted diets in chronic renal failure: a four-year follow-up shows limited indications. *Kidney Int*, (Suppl.) 27: S96, 1989.
  169. Modification of diet in renal disease study group. Effect of dietary protein restriction of nutritional status in the Modification of Diet in Renal Disease study. *Kidney Int*, 52: 778, 1997.
  170. Barsotti C, Ciandrella F, et al. Nutrition treatment of renal failure in type 1 diabetic nephropathy. *Clin Nephrol*, 280: 7, 1988.
  171. Skillman TG, Feldman JM. The Pharmacology of Sulphonylureas. *Am J Med*, 70: 361-372, 1981.
  172. American College of Physicians. Drug Prescribing in renal Failure. Dosing Guidelines for Adults. 3d edition, Bennett WM, Aronoff GR, Golper TA (Eds). Philadelphia, 1984.
  173. Thoren L. Bilancio dei liquidi e degli elettroliti. Ed. Min. Med., 1973.
  174. Mason EE. Fluid, Electrolite and nutrient therapy in surgery. Lea-Febiger, Philadelphia, 1974.
  175. Greco R. Nutrizione parenterale ed enterale. ESR, Roma, Cap. 3, pp. 43, 1992.
  176. Wilkinson W. Body fluids in surgery. IV Edition, Churchill Livingstone, Edimburgo 1973.
  177. Markell MS, Friedman EA. Diabetic Nephropathy: management of the end-stage patient. *Diabetes Care*, 15: 1226-1238, 1992.
  178. Rudberg S, Ullman E, et al. Relationship between early metabolic control and the development of microalbuminuria: a longitudinal study in children with type I diabetes mellitus. *Diabetologia*, 36: 1309-1314, 1993.
  179. Stern MP, Patterson JK et al. Lack of awareness and treat-

- ment of hyperlipidemia in type II diabetes in a community survey. *J Am Med Ass*, 262: 360–364, 1989.
180. Fontbonne A. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. *Diabetologia*, 32: 300–304, 1989.
  181. Semenkovich CF, Ostlund RE, et al. Plasma lipids in patients with type I diabetes mellitus: influence of race, gender and plasma glucose control. *Arch Int Med*, 149: 51–56, 1989.
  182. Dullart RPF, Groener JEM et al. Increased cholesterol transfer activity in complicated type I diabetes mellitus – its relationship with serum lipids. *Diabetologia*, 32: 14–19, 1989.
  183. Imari Y, Coga S, et al. Phenotypes of apolipoprotein E and abnormalities in lipid metabolism in patients with NIDDM. *Metabolism*, 37: 1134–1138, 1988.
  184. Greco R. Nutrizione parenterale ed enterale. ESR, Roma, Cap. 3, pp. 56, 1992.
  185. Khauli RB, Steinmuller DR, et al. A critical look at survival of diabetic with end-stage renal disease: transplantation versus dialysis. *Transplantation*, 41: 598, 1986.
  186. United States Renal Data System. 1999 Annual Data Report. *Am J Kidney Dis*, 34 (suppl 1): S47, 1999.
  187. La Greca. Terapia dell'insufficienza renale nel malato diabetico: quale la scelta migliore? In: Buccianti G., *La malattia diabetica*, Wichtig ed. pp. 61, 1999.
  188. Piccoli GB, Quadrello F, et al. Diabetic patients on dialysis: a changing picture. *Kidney Int*, (Suppl.) 41: S14, 1993.
  189. U.S. Renal Data System. 1997 Annual Data Report NIH, National Institute of Diabetes and Digestive and Kidney diseases, Bethesda, MD, Aprile 1997.
  190. EDTA Registry Report. Figures from annual report on management of renal failure in Europe XXIV, Vienna 1993.
  191. Conte F, et al. Registro Italiano Dialisi e Trapianto. Primo Report *Giornale Italiano di Nefrologia*, 15: 271–280, 1998.
  192. Garancini MP, Calori G, Ruotolo G, et al. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT based population study. *Diabetologia*, 38: 306–313, 1995.
  193. Calori G, Gallus G, Garancini P, et al. Identification of the cohort of type 1 diabetes presenting in Lombardy in 1983–84: a validated assessment. *Diabetes Med* 7: 595–599, 1990.
  194. Spotti D, Marcelli D, Conte F, et al. Uremia e diabete: dati del registro lombardo dialisi e trapianto (RLDT). In: Buccianti G., *La malattia diabetica*, Wichtig ed. pp. 3–8, 1999.
  195. La Greca G, Feriani M, et al. Effects of acetate and bicarbonate dialysate on vascular stability: a prospective study. *Int J Artif Org*, 10: 15, 1987.
  196. Ritz E, Strumpf C, et al. Hypertension and cardiovascular risk factors in hemodialyzed diabetic patients. *Hypertension*, 7 (Suppl II): 118, 1985.
  197. Daujirdas JT. Dialysis Hypotension: a hemodynamic analysis. *Kidney Int*, 39: 223, 1991.
  198. Ifudu O, Dulin A, et al. Diabetics manifest excess weight again on maintenance hemodialysis. *Am Soc Artif Org*, 21: 85, 1992.
  199. Schmitz O, Alberti KG. Insulin resistance in uraemic IDDM: effects of dialysis therapy as assessed by artificial endocrine pancreas. *Acta Endocrinologica*, 105: 371–378, 1984.
  200. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. *Kidney Int*, 52 (Suppl 62): S48, 1997.
  201. Alvestrand A, Wahren J, et al. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. *Am J Physiol*, 246: E174, 1984.
  202. Ritz E et al. Renal failure in diabetic nephropathy. In: *Oxford Textbook of Nephrology*, pp. 1648–1650, 1992.
  203. Held PJ, Port FK, Turenne MN, et al. Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patients mortality with adjustment for comorbidity conditions. *Kidney Int*, 45: 1163, 1994.
  204. Lye WC, Leong SO, et al. A prospective study of peritoneal dialysis-related infections in CAPD patients with diabetes mellitus. *Adv Perit Dial*, 9: 195, 1993.
  205. Scanziani R, Dozio B, Iacuitti G. CAPD in diabetics: use of aminoacids. In: Ota K, Maher J et al. *Current concepts in peritoneal dialysis*. Excerpta Medica, 628–632, 1993.
  206. Mistry CD, Gokal R, Peers EM and the MIDAS study group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. *Kidney Int*, 46: 496, 1994.
  207. Matthijs E, Dolkart R et al. Potential hazards of glycerol dialysate in diabetic CAPD patients. *Perit Dial Bull*, 7: 16, 1987.
  208. Van Biesen W, Faict D et al. Further animal and human experience with 0.6% aminoacids/1.4% glycerol peritoneal dialysis solutions. *Perit Dial Int*, 17 (suppl 2): S56–S62, 1997.
  209. Balodimus MC. Diabetic nephropathy. In: Marble A, White P, Bradley RF, Krall LP (eds). *Joslin's Diabetes*. Philadelphia: Lea and Febiger, pp. 526–561, 1971.
  210. Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin-dependent diabetes mellitus. *Ann Intern Med*, 10: 788–796, 1989.
  211. Khauli RB, Steinmuller DR, Novick AC, et al. A critical look at survival of diabetics with end-stage renal disease: transplantation versus dialysis therapy. *Transplantation*, 41: 598–602, 1986.
  212. Retting RA, Levinsky NG (eds). *Kidney Failure and the*

- Federal Government Access to Kidney Transplantation. Institute for Medicine (U.S.), National Academy of Science, pp. 167–186, 1991.
213. Cecka JM, Terasaki PL. The UNOS Scientific Renal Transplant registry-1991. In: Terasaki PL (eds). *Clinical Transplant 1991*. Los Angeles CA: UCLA Tissue Typing Laboratory, pp. 1–11, 1992.
  214. Maryniak RK, Mendoza N, Clyne D, et al. Recurrence of diabetic nodular glomerulosclerosis in a renal transplant. *Transplantation*, 39: 35–38, 1985.
  215. Najarian JS, Sutherland DE, Simmons RL, et al. Ten year experience with renal transplantation in juvenile onset diabetics. *Ann Surg*, 190: 487, 1979.
  216. Mauer SM, Barbosa J, Vernier RL, et al. Development of diabetic vascular lesions in normal kidneys transplanted into patients with diabetes mellitus. *N Engl J Med*, 295: 916, 1976.
  217. Najarian JS, Kaufman DB, Fryd DS, et al. Long-term survival following kidney transplantation in 100 type 1 diabetic patients. *Transplantation*, 47: 106, 1989.
  218. Remuzzi G, Rugenenti P, Mauer SM. Pancreas and kidney/pancreas transplant. Experimental medicine or real improvement? *Lancet*, 343: 27, 1994.
  219. Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patient with insulin-dependent diabetes. *N Engl J Med*, 321: 80, 1989.
  220. Vlassara H, Fuh H, Makita Z, et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complication. *Proc Natl Acad Sci USA*, 89: 12043–12047, 1992.
  222. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation and products in patients with diabetic nephropathy. *N Engl J Med*, 325: 836–842, 1991.
  223. Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. *Metabolism*, 40: 1016–1019, 1991.
  224. Corbett JA, Tilton RG, Chang K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. *Diabetes*, 4: 552–556, 1992.
  225. Lyons TJ, Dailie KE, Dyer DG, et al. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. *J Clin Invest*, 87: 1910–1915, 1991.
  226. Basadonna G, Matas AJ, Najarian JS. Kidney transplantation in diabetic patients: the University of Minnesota experience. *Kidney Int (Suppl.)* 38: S193, 1992.
  227. Grenfell A, Bewich N, Snowden S, et al. Renal replacement for diabetic patients: Experience at King's College Hospital 1980–1989. *Q J Med*, 85: 861, 1992.
  227. Zeier M, Jones E, Ritz E. Autosomal dominant polycystic kidney disease – the patients on renal replacement therapy. *Nephrol Dial Transplant*, 11 (Suppl. 6): 18, 1983.
  228. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med*, 341: 1725, 1999.
  229. Williams ME. Management of the diabetic transplant recipient. *Kidney Int*, 48: 1660, 1995.
  230. Manske CL, Wang Y, Rector T, et al. Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. *Lancet*, 340: 998, 1992.
  231. Coch M, Gradaus F, Schoebel FC, et al. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. *Nephrol Dial Transplant*, 12: 1187, 1997.
  232. United States renal data System. 1998 Annual Data report. *Am J Kidney Dis*, 32 (Suppl 1): S91, 1998.
  233. Rubin RH. Infectious disease complications of renal transplantation. *Kidney Int*, 44: 221, 1993.
  234. The U.S. Multicentre Liver FK506 liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. *N Engl J Med*, 331: 1110, 1994.
  235. Porayko MK, Textor SC, Krom RA et al. Nephrotoxic effects of primary immunosuppression with FK506 and cyclosporine regimens after liver transplantation. *Mayo Clin Proc*, 69: 105, 1994.
  236. Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. *Transplantation*, 55: 205, 1993.
  237. Moxey-Mims MM, Kay C, Light JA, Kher KK. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). *Transplantation*, 65: 617, 1998.
  238. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of sirolimus/cyclosporine combination regimen for renal transplantation. *Transplantation*, 66: 1040, 1998.
  239. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials. *BMJ*, 318: 1104, 1999.
  240. Textor SC, Weisner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporin in liver transplant recipients. *Transplantation*, 55: 1332, 1993.
  241. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporin and rapamycin in a chronic nephrotoxicity model. *Transplantation*, 62: 311, 1996.
  242. Gruesner A, Sutherland DER. Pancreas transplants for United States (U.S. and non U.S. cases) as reported to the

- International Pancreas Transplant Registry (IPTR) and to the United Network for Organ Sharing (UNOS). In: *Clinical Transplants*. Cecka M, Terasaki P, Eds. Los Angeles, UCLA Tissue Typing Laboratory, 1998.
243. Pozza G, Traeger J, Dubernard JM, et al. Endocrine response of type 1 (insulin-independent) diabetic patients following successful pancreas transplantation. *Diabetologia*, 24: 244–248, 1983.
  244. Diem P, Redmon JB, Abid M, et al. Glucagon, catecholamine and pancreatic polypeptide secretion in type 1 diabetic recipients of pancreas allografts. *J Clin Invest*, 86: 2008–2013, 1990.
  245. Kendall DM, Rooney DP, Smets YF, et al. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type 1 diabetes and autonomic neuropathy. *Diabetes*, 46: 249–257, 1997.
  246. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. *Ann Neurol*, 42: 727–736, 1997.
  247. Bilous RW, Mauer SM, Sutherland DE, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin dependent diabetes. *N Engl J Med*, 321: 80–85, 1988.
  248. Ramsay RC, Goetz FC, Sutherland DE, et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. *N Engl J Med*, 318: 208–214, 1988.
  249. Robertson RP, Davis C, Larsen J, et al. Pancreas and islet transplantation for patients with diabetes mellitus (Technical Review). *Diabetes Care*, 23: 112–116, 2000.
  250. Sollinger HW, Odorico JS, Knechtle SJ, et al. Experience with 500 simultaneous pancreas-kidney transplants. *Ann Surg*, 228: 284–296, 1998.
  251. Cheung DH, Sutherland DE, Gillingham KJ, et al. Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. *Kidney Int*, 41: 924–929, 1992.
  252. Guessner RW, Dunn DL, Guessner AC, et al. Recipient risk factors have an impact on technical failure and patient and graft survival rates in bladder-drained pancreas transplant. *Transplantation*, 57: 1598–1606, 1994.